Vesugen
Lab-Tested ≥98% Purity · Certificate of Analysis Included · Global Shipping
Vesugen (Lys-Glu-Asp) — Vascular Bioregulator Peptide for Cardiovascular Research
Vesugen is a synthetic tripeptide bioregulator (Lys-Glu-Asp) developed at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson. As a vascular-specific bioregulator, Vesugen has been characterized for its regulatory effects on endothelial cell gene expression, vascular tone maintenance, and blood vessel wall integrity. Published research in Bulletin of Experimental Biology and Medicine and Advances in Gerontology has documented its capacity to normalize endothelial function, restore nitric oxide signaling, and preserve vascular architecture in aged experimental models.
Mechanism of Action
Vesugen interacts with DNA sequences in promoter regions of genes critical for endothelial cell function and vascular homeostasis. The KED tripeptide modulates transcription of endothelial nitric oxide synthase (eNOS), prostacyclin synthase (PGIS), and vascular endothelial growth factor receptors through chromatin remodeling at endothelial-specific gene loci. Research has demonstrated that Vesugen restores age-diminished eNOS expression and enzymatic activity, improving endothelium-dependent vasodilation capacity while simultaneously downregulating pro-thrombotic endothelin-1 (ET-1) expression.
Key Research Areas
- Endothelial Function: In-vitro studies on human umbilical vein endothelial cells (HUVECs) have demonstrated that Vesugen enhances NO production, reduces endothelial activation markers (VCAM-1, ICAM-1, E-selectin), and preserves endothelial barrier function under inflammatory stress conditions.
- Vascular Aging: Research in aged murine models has shown improved flow-mediated dilation, restored aortic compliance, and reduced arterial wall thickening following chronic Vesugen administration, with effects correlated to normalized eNOS/ET-1 expression ratios.
- Anti-Atherogenic Effects: Studies have documented reduced monocyte adhesion to Vesugen-treated endothelial monolayers, decreased foam cell formation, and attenuated intimal thickening in hyperlipidemic animal models.
- Microcirculation: Intravital microscopy studies have observed improved capillary perfusion patterns, normalized leukocyte rolling velocity, and reduced microvascular permeability in aged tissues following Vesugen treatment.
Technical Specifications
- Dosage per vial: 10mg lyophilized powder
- Purity: ≥98% (HPLC verified)
- Sequence: Lys-Glu-Asp (KED tripeptide)
- Molecular Weight: 390.39 Da
- Storage: -20°C, protected from light
Why Researchers Choose Peptides BioLab
Every batch of Vesugen supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our product is supplied as a lyophilized powder for maximum stability, shipped worldwide in temperature-controlled packaging.
Related Research Peptides
Researchers studying vascular bioregulation may also find these compounds relevant: Cardiogen, BPC-157, and GHK-Cu. For a complete overview, browse our Recovery Research collection.
For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.
Every Peptides BioLab product includes a Certificate of Analysis (CoA) with HPLC and MS data confirming ≥98% purity. The CoA is available in the product tabs as the 2nd image, or contact our team to request a copy.
Shipping: We ship worldwide from our state-of-the-art facilities. Orders are processed within 1–2 business days. Express and standard shipping options available at checkout.
Storage: Store lyophilized peptides at -20°C for long-term storage. Once reconstituted, store at 2–8°C and use within 30 days. Keep away from direct sunlight.
